[Hiring] Vice President, Biometrics @Braveheart Bio

Role Description

The Vice President of Biometrics will provide strategic and operational leadership across statistical activities as the company transitions into Phase III clinical trials. This role will be responsible for defining and executing the integrated biometrics strategy, overseeing CRO and vendor partnerships, ensuring data integrity and regulatory readiness, and serving as a key leader on the clinical development team. The ideal candidate brings deep late-stage expertise, strong cross-functional leadership, and a hands-on mindset well suited for a lean, fast-growing biotech organization.

Key responsibilities:

• Provide strategic leadership for biometrics across all clinical development programs, with primary focus on Phase III execution.
• Define and implement an integrated biometrics strategy supporting clinical trial design, data quality, statistical analysis, and regulatory submissions.
• Serve as a core member of the clinical leadership team, partnering closely with Clinical Operations, Data Management, Regulatory Affairs, Safety, and Medical Affairs.
• Lead and oversee CROs and external vendors responsible for biostatistics statistical programming and related biometrics activities.
• Oversee development and review of key deliverables including SAPs, DMPs, CRFs, TFL shells, interim analyses, database locks, and clinical study reports.
• Ensure data integrity, statistical rigor, and compliance with GCP, ICH, and global regulatory requirements.
• Provide strategic input into study design, endpoint selection, sample size calculations, and adaptive or innovative trial methodologies as appropriate.
• Support regulatory interactions and submissions, including briefing documents, responses to health authority questions, and advisory committee preparations.
• Establish scalable biometrics processes, standards, and SOPs to support late-stage development and future pipeline growth.
• Build, mentor, and lead internal biostatistics capabilities over time, as appropriate to company growth.

Qualifications

• Bachelor’s degree or advanced degree, ideally in biostatistics, statistics, mathematics, or a related quantitative discipline.
• Minimum of 12 years of progressive experience in biostatistics within the biotechnology or pharmaceutical industry.
• Significant experience leading biostatistics activities for Phase III clinical trials and regulatory submissions.
• Demonstrated success managing CROs and external vendors in a late-stage development environment.
• Proven track record as a strategic biometrics leader, contributing substantively to complex study designs, endpoint development, and statistical strategy across global development programs.
• Strong understanding of global regulatory expectations related to clinical data, statistical analyses, and inspection readiness.
• Proven ability to operate strategically while remaining hands-on in a lean organization.
• Strong written and verbal communication skills with a collaborative, team-oriented approach.
• Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
• Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude.

Requirements

• Prior experience serving as a functional or biometrics lead in regulatory interactions with FDA and ex-U.S. health authorities.
• Experience in cardiovascular, rare disease, or genetically driven conditions.
• Background in small or mid-sized biotech companies transitioning into late-stage development.
• Experience building or scaling internal biometrics functions and infrastructure.
• Familiarity with innovative trial designs and modern statistical methodologies.

Benefits

• Base Salary Range: $300K - $375K.
• This role is eligible for a competitive total rewards package, including an annual bonus, equity, and a comprehensive benefits offering.

Company Description

Braveheart Bio is a Bay Area–based biopharmaceutical company pioneering best-in-class therapies for cardiovascular disease. Our lead program is a next-generation myosin inhibitor, licensed from Hengrui Pharma, being developed to transform the treatment of hypertrophic cardiomyopathy (HCM)—the most common inherited cardiac disease.

Currently in Phase 3 clinical development in China for the more common obstructive form of HCM, our candidate has demonstrated a compelling clinical profile that may position it as a best-in-class therapy with meaningful differentiation.

With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.